Wang Y - Search Results

1

A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer.

Wang Y, Herrstedt J, Havsteen H, DePoint Christensen R, Mirza MR, Lund B, Maenpaa J, Kristensen G. Wang Y, et al. BMC Cancer. 2014 Dec 11;14:937. doi: 10.1186/1471-2407-14-937. BMC Cancer. 2014. PMID: 25494701 Free PMC article. Clinical Trial.

2

TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival.

Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL, Kristensen GB. Wang Y, et al. Br J Cancer. 2004 Feb 9;90(3):678-85. doi: 10.1038/sj.bjc.6601537. Br J Cancer. 2004. PMID: 14760384 Free PMC article.

3

Effect of the codon 72 polymorphism (c.215G>C, p.Arg72Pro) in combination with somatic sequence variants in the TP53 gene on survival in patients with advanced ovarian carcinoma.

Wang Y, Kringen P, Kristensen GB, Holm R, Baekelandt MM, Olivier M, Skomedal H, Hainaut P, Tropé CG, Abeler VM, Nesland JM, Børresen-Dale AL, Helland A. Wang Y, et al. Hum Mutat. 2004 Jul;24(1):21-34. doi: 10.1002/humu.20055. Hum Mutat. 2004. PMID: 15221786

4

PIK3CA mutations in advanced ovarian carcinomas.

Wang Y, Helland A, Holm R, Kristensen GB, Børresen-Dale AL. Wang Y, et al. Hum Mutat. 2005 Mar;25(3):322. doi: 10.1002/humu.9316. Hum Mutat. 2005. PMID: 15712344

5

Protein expression and prognostic value of genes in the erb-b signaling pathway in advanced ovarian carcinomas.

Wang Y, Kristensen GB, Helland A, Nesland JM, Børresen-Dale AL, Holm R. Wang Y, et al. Am J Clin Pathol. 2005 Sep;124(3):392-401. doi: 10.1309/BL7E-MW66-LQX6-GFRP. Am J Clin Pathol. 2005. PMID: 16191507

6

TP53 mutations in ovarian carcinomas from sporadic cases and carriers of two distinct BRCA1 founder mutations; relation to age at diagnosis and survival.

Kringen P, Wang Y, Dumeaux V, Nesland JM, Kristensen G, Borresen-Dale AL, Dorum A. Kringen P, et al. Among authors: wang y. BMC Cancer. 2005 Oct 17;5:134. doi: 10.1186/1471-2407-5-134. BMC Cancer. 2005. PMID: 16229746 Free PMC article.

7

TP53 mutations and codon 72 genotype--impact on survival among ovarian cancer patients.

Wang Y, Kristensen GB, Børresen-Dale AL, Helland A. Wang Y, et al. Ann Oncol. 2007 May;18(5):964-6. doi: 10.1093/annonc/mdm134. Ann Oncol. 2007. PMID: 17488735 Free article. No abstract available.

8

High levels of genomic aberrations in serous ovarian cancers are associated with better survival.

Baumbusch LO, Helland Å, Wang Y, Liestøl K, Schaner ME, Holm R, Etemadmoghadam D, Alsop K, Brown P; Australian Ovarian Cancer Study Group; Mitchell G, Fereday S, DeFazio A, Bowtell DD, Kristensen GB, Lingjærde OC, Børresen-Dale AL. Baumbusch LO, et al. Among authors: wang y. PLoS One. 2013;8(1):e54356. doi: 10.1371/journal.pone.0054356. Epub 2013 Jan 23. PLoS One. 2013. PMID: 23372714 Free PMC article.

9

Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only.

Smogeli E, Cvancarova M, Wang Y, Davidson B, Kristensen G, Lindemann K. Smogeli E, et al. Among authors: wang y. Int J Gynecol Cancer. 2018 Nov;28(9):1789-1795. doi: 10.1097/IGC.0000000000001356. Int J Gynecol Cancer. 2018. PMID: 30365455

10

Pelvic exenteration for vulvar cancer: Postoperative morbidity and oncologic outcome - A single center retrospective analysis.

Valstad H, Eyjolfsdottir B, Wang Y, Kristensen GB, Skeie-Jensen T, Lindemann K. Valstad H, et al. Among authors: wang y. Eur J Surg Oncol. 2023 Sep;49(9):106958. doi: 10.1016/j.ejso.2023.06.010. Epub 2023 Jun 13. Eur J Surg Oncol. 2023. PMID: 37349160 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

271,569 results

Search Page